Abstract:Introduction: Arylboronates afford rapid aqueous F-18-labeling via the creation of a highly polar F-18-aryltrifluoroborate anion (F-18-ArBF3-).Hypothesis: Radiosynthesis of an F-18-ArBF3- can be successfully applied to a clinically relevant peptide. To test this hypothesis we labeled dimeric-cylcoRGD, [c(RGDfK)](2)E because a) it is molecularly complex and provides a challenging substrate to test the application of this technique and b) [c(RGDfK)](2)E has already been labeled via several F-18-labeling methods which provide for a preliminary comparison.Goal: To validate this labeling method in the context of a complex and clinically relevant tracer to show tumor-specific uptake ex vivo with representative PET images in vivo.Methods: An arylborimidine was conjugated to [c(RGDfK)](2)E to give the precursor [c(RGDfK)](2)E-ArB(dan) which was aliquoted and stored at-20 degrees C. Aliquots of 10 or 25 nmol containing only micrograms of precursor were labeled using relatively low levels of F-18-activity. Following purification eight mice (pre-blocked/unblocked) with U87M xenograft tumors were injected with [c(RGDfK)(2)E-F-18-ArBF3- (n = 4) for ex vivo tissue dissection. Two sets of mice (pre-blocked/unblocked) were also imaged with PET-CT (n = 2).Results: The [c(RGDfK)](2)E-ArB(dan) is converted within 15 min to [c(RGDfK)](2)E-F-18-ArBF3- in isolated radiochemical yields of similar to 10% (n = 3) at a minimum effective specific activity of 0.3 Ci/mu mol. Biodistribution shows rapid clearance to the bladder via the kidney resulting in high tumor-to-blood and tumor-to-muscle ratios of >9 and >6 respectively while pre-blocking with [c(RGDfK)](2)E showed high tumor specificity. PET imaging showed good contrast between tumor and non-target tissues confirming the biodistribution data.Conclusion: An arylborimidine-RGD peptide is rapidly F-18-labeled in one step in good yield at useful specific activity. Biodistribution studies with blocking controls show tumor specificity which is corroborated by PET images.Advances in Knowledge and Implications for patient Care: Despite many antecedent examples of labeled RGD tracers this work is the first to show direct aqueous labeling of bisRGD with an F-18-ArBF3-. Labeling occurs in near record rapidity (45 min) at useful effective specific activities and competitive yields for high contrast tumor specific images. As bisRGD has been imaged in humans with several prosthetics this work suggests potential clinical applications of tracers appended with an F-18-ArBF3- More generally the ability to label a molecularly complex tracer suggests that this method could be useful to label many other peptides. Furthermore these results portend the development of kits that use only microgram quantities of lyophilized precursor for on demand labeling. The ability to perform one-step aqueous labeling in under an hour to provide tracers with high T:NT ratios has important implications for developing radiotracers for use in fundamental research and in preclinical tracer studies. (C) 2013 Elsevier Inc. All rights reserved.

Efficient construction of F-18 labeled TRC105-Fab based on tetrazine trans-cyclooctene ligation

PET imaging of CD105/endoglin expression with a 61/64 Cu-labeled Fab antibody fragment

PET of CD105 Expression with a 61/64Cu-Labeled Fab Antibody Fragment

Positron Emission Tomography Imaging of Tumor Angiogenesis with a (61/64)Cu-Labeled F(ab')(2) Antibody Fragment.

Positron Emission Tomography Imaging of CD105 Expression with 89 Zr-Df-TRC105

ImmunoPET and Near-Infrared Fluorescence Imaging of CD105 Expression Using a Monoclonal Antibody Dual-Labeled with (89)zr and IRDye 800CW.

Positron Emission Tomography and Optical Imaging of Tumor CD105 Expression with a Dual-Labeled Monoclonal Antibody.

Positron Emission Tomography Imaging of CD105 Expression During Tumor Angiogenesis

Positron Emission Tomography Imaging of Tumor Angiogenesis with a 66Ga-Labeled Monoclonal Antibody.

Imaging Tumor Angiogenesis in Breast Cancer Experimental Lung Metastasis with Positron Emission Tomography, Near-Infrared Fluorescence, and Bioluminescence

Dual Mode Fluorescent Pet Tracers: Efficient Modular Synthesis, Facile F-18-Radiolabelling, in Vivo Pet Imaging and Ex Vivo Fluorescence

Positron Emission Tomography Imaging Of Cd105 Expression With A Cu-64-Labeled Monoclonal Antibody: Nota Is Superior To Dota

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42

Pretargeted Imaging with Gallium-68-Improving the Binding Capability by Increasing the Number of Tetrazine Motifs

Single Step 18F-Labeling of Dimeric Cyclorgd for Functional PET Imaging of Tumors in Mice.

eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors

Synthesis and preclinical evaluation of a heterodimeric radioligand targeting fibroblast activation protein and integrin-αvβ3

Studies of 99mTc labeled carcinoembyronic antigen monoclonal antibody C50 fragment Fab' and biodistrobution

Development and Evaluation of DOTA-FAPI-Maleimide as a Novel Radiotracer for Tumor Theranostic with Extended Circulation

ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment

Synthesis and preclinical evaluation of novel 18 F-labeled fibroblast activation protein tracers for positron emission tomography imaging of cancer-associated fibroblasts